Takeda Pharmaceutical Company Limited
TKPHF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $6,833,749,813 | $6,386,744,750 | $7,439,780,396 | $6,662,072,431 |
| - Cash | $681,486,000 | $350,008,000 | $385,113,000 | $494,126,000 |
| + Debt | $4,645,320,000 | $4,505,942,000 | $4,515,265,000 | $4,840,148,000 |
| Enterprise Value | $10,797,583,813 | $10,542,678,750 | $11,569,932,396 | $11,008,094,431 |
| Revenue | $1,112,796,000 | $1,106,685,000 | $1,053,399,000 | $1,144,124,000 |
| % Growth | 0.6% | 5.1% | -7.9% | – |
| Gross Profit | $732,735,000 | $722,010,000 | $671,321,000 | $727,250,000 |
| % Margin | 65.8% | 65.2% | 63.7% | 63.6% |
| EBITDA | $316,467,000 | $439,424,000 | $73,346,000 | $244,958,000 |
| % Margin | 28.4% | 39.7% | 7% | 21.4% |
| Net Income | -$11,802,000 | $124,243,000 | -$103,155,000 | $23,789,000 |
| % Margin | -1.1% | 11.2% | -9.8% | 2.1% |
| EPS Diluted | -7.48 | 78.23 | -65.25 | 14.78 |
| % Growth | -109.6% | 219.9% | -541.5% | – |
| Operating Cash Flow | $378,228,000 | $215,423,000 | $222,159,000 | $383,756,000 |
| Capital Expenditures | -$52,825,000 | -$75,068,000 | -$92,724,000 | -$56,651,000 |
| Free Cash Flow | $325,403,000 | $140,355,000 | $129,435,000 | $327,105,000 |